194 related articles for article (PubMed ID: 9358193)
1. Problems with long-term levodopa therapy for Parkinson's disease.
Marsden CD
Clin Neuropharmacol; 1994; 17 Suppl 2():S32-44. PubMed ID: 9358193
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Parkinson's disease: levodopa as the first choice.
Katzenschlager R; Lees AJ
J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
[TBL] [Abstract][Full Text] [Related]
3. Clinical aspects of motor fluctuations in Parkinson's disease.
Poewe WH
Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
Cedarbaum JM
Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
[TBL] [Abstract][Full Text] [Related]
5. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
[TBL] [Abstract][Full Text] [Related]
6. Optimizing long-term therapy for Parkinson disease: levodopa, dopamine agonists, and treatment-associated dyskinesia.
Stacy M; Galbreath A
Clin Neuropharmacol; 2008; 31(1):51-6. PubMed ID: 18303491
[TBL] [Abstract][Full Text] [Related]
7. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
[TBL] [Abstract][Full Text] [Related]
8. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
9. [Influence of protein-restricted diet on motor response fluctuations in Parkinson's disease].
Hirata H; Asanuma M; Kondo Y; Ogawa N
Rinsho Shinkeigaku; 1992 Sep; 32(9):973-8. PubMed ID: 1300270
[TBL] [Abstract][Full Text] [Related]
10. Motor complications of Parkinson's disease.
Martignoni E; Riboldazzi G; Calandrella D; Riva N
Neurol Sci; 2003 May; 24 Suppl 1():S27-9. PubMed ID: 12774208
[TBL] [Abstract][Full Text] [Related]
11. Should levodopa be used anymore?
Zegers de Beyl D
Acta Neurol Belg; 2002 Dec; 102(4):163-6. PubMed ID: 12534242
[TBL] [Abstract][Full Text] [Related]
12. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
[TBL] [Abstract][Full Text] [Related]
13. [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].
Zappia M; Nicoletti A; Muñoz-S D; Tapia-Núñez J
Rev Neurol; 2009 Jul 1-15; 49(1):33-40. PubMed ID: 19557698
[TBL] [Abstract][Full Text] [Related]
14. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
15. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
Rinne UK
J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
[TBL] [Abstract][Full Text] [Related]
16. Complications and limitations of drug therapy for Parkinson's disease.
Jankovic J
Neurology; 2000; 55(12 Suppl 6):S2-6. PubMed ID: 11188970
[TBL] [Abstract][Full Text] [Related]
17. [Problems of long-term levodopa therapy in Parkinson's disease].
Nakamura Y
Nihon Rinsho; 1997 Jan; 55(1):65-71. PubMed ID: 9014425
[TBL] [Abstract][Full Text] [Related]
18. Limitations of current Parkinson's disease therapy.
Rascol O; Payoux P; Ory F; Ferreira JJ; Brefel-Courbon C; Montastruc JL
Ann Neurol; 2003; 53 Suppl 3():S3-12; discussion S12-5. PubMed ID: 12666094
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
Mondal BK; Mondal KN
Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
[TBL] [Abstract][Full Text] [Related]
20. The spectrum of levodopa-induced dyskinesias.
Fahn S
Ann Neurol; 2000 Apr; 47(4 Suppl 1):S2-9; discussion S9-11. PubMed ID: 10762127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
